263 related articles for article (PubMed ID: 3526755)
21. Comparison of the hemocytometer and tube modifications of the leukocyte adherence inhibition assay -- II. Application of both modifications for detection of anti-tumor immunity in man.
Schimke R; Holán V; Sibl O; Hasek M; Ambrosius H
Neoplasma; 1981; 28(3):257-64. PubMed ID: 7027056
[TBL] [Abstract][Full Text] [Related]
22. [Inhibition of the adherence of leukocytes labelled with Cr-51 in colorectal cancer].
Mounielou PM; Clemente F; Estival A; Ribet A
Gastroenterol Clin Biol; 1984 Oct; 8(10):736-41. PubMed ID: 6396147
[TBL] [Abstract][Full Text] [Related]
23. The leukocyte adherence-inhibition assay as a diagnostic test for multiple sclerosis: study of a substance found in MS blood.
Angers JW; Korik L; Franklin LS; Reid WE; Urbania C; Turner R; Angers AH; Soviero S; Lyons M; Levy AL
J Lab Clin Med; 1979 Apr; 93(4):528-34. PubMed ID: 372467
[TBL] [Abstract][Full Text] [Related]
24. Immunity to tumor-associated antigens in vasectomized men.
Anderson DJ; Alexander NJ; Fulgham DL; Vandenbark AA; Burger DR
J Natl Cancer Inst; 1982 Sep; 69(3):551-5. PubMed ID: 6180209
[TBL] [Abstract][Full Text] [Related]
25. An isolated enriched organ-specific cancer neoantigen of human lung cancer for leukocyte adherence inhibition assays.
Dubois AE; Thomson DM; Sutherland ME; Scanzano R
Cancer Res; 1985 Jun; 45(6):2661-9. PubMed ID: 3886136
[TBL] [Abstract][Full Text] [Related]
26. Application of tube LAI assay in larynx cancer patients.
Hasek M; Holán V; Síbl O; Kousalová M
Neoplasma; 1981; 28(6):685-8. PubMed ID: 7040994
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of the LAI test in patients with benign and malignant breast diseases.
Kovarík J; Lauerová L; Ninger E; Munzarová M; Feit J; Zemanová D; Wotke R
Neoplasma; 1983; 30(2):163-7. PubMed ID: 6843721
[TBL] [Abstract][Full Text] [Related]
28. Immunological response of patients with tumors of the urogenital tract: a follow-up of cell-mediated antitumor immunity by the LAI test.
Holán V; Heyberger K; Bubeník J; Hasek M; Kanka J; Laurová L
Neoplasma; 1977; 24(1):71-9. PubMed ID: 320490
[TBL] [Abstract][Full Text] [Related]
29. Detection of specific immunoreactivity by LAI assay in patients with malignant melanoma of uveal tissue.
Kalafut F; Cernák A; Pham Manh Hung
Neoplasma; 1979; 26(3):299-305. PubMed ID: 394010
[TBL] [Abstract][Full Text] [Related]
30. [Modulating action of interferon preparations on cellular reactions of antitumor immunity].
Mkrtchian LN; Ter-Pogosian ZR; Sarkisian OM; Gevorkian RA; Movsesian EA
Vopr Onkol; 1983; 29(8):7-11. PubMed ID: 6351429
[TBL] [Abstract][Full Text] [Related]
31. Cell-mediated immune reactions directed against syngeneic methylcholanthrene-induced mouse sarcomas: low reproducibility of the results obtained with the tube modification of leukocyte adherence inhibition assay.
Simová J; Bubeník J
Neoplasma; 1979; 26(5):635-9. PubMed ID: 392326
[TBL] [Abstract][Full Text] [Related]
32. Requirement for autologous cancer extracts and lipoxygenation of arachidonic acid for human T-cell responses in leukocyte adherence inhibition and transmembrane potential change assays.
Shenouda G; Thomson DM; MacFarlane JK
Cancer Res; 1984 Mar; 44(3):1238-45. PubMed ID: 6420056
[TBL] [Abstract][Full Text] [Related]
33. Humoral leukocyte adherence inhibition (H-LAI) test in screening of high risk group for lung cancer.
Kubasova T; Bank J; Köteles GJ; Horváth M
Neoplasma; 1990; 37(2):173-8. PubMed ID: 2188164
[TBL] [Abstract][Full Text] [Related]
34. Heterogenicity and specificity of tumor associated antigens (TAA) and fetal antigens (FA) as detected by 51Cr-LAI test and EM test in mouse sarcomas.
Werner H; Schulze HA
Arch Geschwulstforsch; 1981; 51(6):481-4. PubMed ID: 6174101
[TBL] [Abstract][Full Text] [Related]
35. [Studies on immunospecificity of skin test using tumor extract in gynecological malignancy (author's transl)].
Yuzawa H
Nihon Sanka Fujinka Gakkai Zasshi; 1980 May; 32(5):611-8. PubMed ID: 6165790
[TBL] [Abstract][Full Text] [Related]
36. Antigenic specificity and cellular mechanisms in leukocyte adherence inhibition analysis of immunity to simple proteins and hapten-protein conjugates.
Powell A; Sloss AM; Smith RN; Murrell H
Cancer Res; 1979 Feb; 39(2 Pt 2):570-5. PubMed ID: 83911
[TBL] [Abstract][Full Text] [Related]
37. A comparison between the macrophage migration inhibition test (MMI) and the leucocyte adherence inhibition test (LAI) in patients with melanoma and carcinoma of the colon.
Isbister WH
N Z Med J; 1978 Oct; 88(622):327-30. PubMed ID: 366475
[TBL] [Abstract][Full Text] [Related]
38. Leukocyte adherence inhibition (LAI) test, LAI. Trypsin and LAI. Humoral test in large term immunotherapy with levamisole on breast and colon cancer.
De Carli HO; Restbergs V
Rev Esp Oncol; 1983; 30(1):25-39. PubMed ID: 6387830
[TBL] [Abstract][Full Text] [Related]
39. Humoral antitumor immune responses in patients with breast cancer measured with the leukocyte adherence inhibition technique.
Kotlar HK; Sanner T
J Natl Cancer Inst; 1981 Feb; 66(2):265-71. PubMed ID: 7005505
[TBL] [Abstract][Full Text] [Related]
40. Antitumor immune response to colorectal cancer antigen detected by the leukocyte adherence inhibition test (LAI) in groups at high risk for colorectal cancer.
Shani A; Fink A; Bass D; Gottesfeld F; Becker S; Levy E; Bentwich Z; Rozen P; Fireman Z; Hallak A
Cancer Detect Prev; 1986; 9(5-6):485-90. PubMed ID: 3779710
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
